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Abstract
Background: Sustainable DNA resources and reliable high-throughput genotyping methods are
required for large-scale, long-term genetic association studies. In the genetic dissection of common
disease it is now recognised that thousands of samples and hundreds of thousands of markers,
mostly single nucleotide polymorphisms (SNPs), will have to be analysed. In order to achieve these
aims, both an ability to boost quantities of archived DNA and to genotype at low costs are highly
desirable. We have investigated Φ29 polymerase Multiple Displacement Amplification (MDA)-
generated DNA product (MDA product), in combination with highly multiplexed BeadArray™
genotyping technology. As part of a large-scale BeadArray genotyping experiment we made a direct
comparison of genotyping data generated from MDA product with that from genomic DNA
(gDNA) templates.
Results: Eighty-six MDA product and the corresponding 86 gDNA samples were genotyped at 345
SNPs and a concordance rate of 98.8% was achieved. The BeadArray sample exclusion rate, blind
to sample type, was 10.5% for MDA product compared to 5.8% for gDNA.
Conclusions: We conclude that the BeadArray technology successfully produces high quality
genotyping data from MDA product. The combination of these technologies improves the feasibility
and efficiency of mapping common disease susceptibility genes despite limited stocks of gDNA
samples.
Background
In order to locate the disease variants involved in complex
common disease it is now generally accepted that very
large sample numbers will be required [1-4]. Not only do
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the sample collections need to provide high quality
gDNA, for the purpose of accurate genotyping, they also
need to be sustainable. If, for example, one million SNPs
were to be genotyped in a whole genome association scan
and only 1 ng were required per SNP genotype, 1 mg of
DNA would be required from each clinical sample. Given
that the gDNA yield from a typical blood sample of 8 ml
is approximately 200 µg, and that the typical yield from a
mouth-swab is just 10 µg, there is clearly a short-fall in
available quantities unless other means are employed to
amplify the DNA resource. Moreover, many existing and
effectively irreplaceable DNA sample collections, which
have been used in previous studies and are now depleted,
may consist of only nanogram quantities of gDNA.
At present, the gold standard method for generating
gDNA from whole blood samples is through the process
of immortalisation by transformation of the peripheral
blood lymphocytes with Epstein-Barr Virus (EBV) [5].
Although this method of transfecting EBV creates an
unlimited resource of gDNA, the procedure is costly,
lengthy and not applicable to existing collections for
which the gDNA has already been extracted. If there was a
reliable method to enzymatically amplify the whole
genome from nanogram-levels of gDNA and directly from
clinical samples to microgram amounts then this would
enable the use of archived gDNA in future studies, as well
as providing an accelerated route to full use of newly col-
lected clinical samples for high-throughput genotyping.
Molecular Staging, Inc. (MSI) (New Haven, CT, USA) have
developed a method for whole genome amplification by
Φ29 polymerase Multiple Displacement Amplification
(MDA). It has been reported by the company that this
method can reliably amplify the whole genome from
gDNA, whole blood and other clinical samples [6-8]. Each
DNA sample should give similar yields of product in all
reactions with little dependency on the quantity of start-
ing template [6,7]. Moreover, the MDA reaction should
give complete coverage of the genome with little regional
bias [6], which is critical when the product is to be used
for high-throughput SNP genotyping. We set up a series of
experiments with MSI in order to validate their claims that
MDA product from gDNA is a viable alternative template
to un-manipulated gDNA in SNP genotyping.
Recent studies have been conducted using MDA product
from Amersham [9,10], and report the high level of accu-
racy achieved when these products are genotyped using
TaqMan or multiplex, four-colour fluorescent minise-
quencing with six and 45 SNPs, respectively. However,
without DNA resource limitations, a genotyping bottle-
neck exists mostly as a result of time- and assay set-up
costs and hence, in order to achieve large-scale genotyp-
ing, highly multiplexed assays are required. In such multi-
plexed assays, there is greater potential for erosion of
genotyping quality, due to reduced substrate integrity. The
validation of the use of amplified DNA resources with
such highly multiplexed methods is, therefore, essential.
The BeadArray genotyping platform of Illumina™ Inc.
(San Diego, CA, USA) offers a high-throughput, highly
multiplexed and highly automated genotyping service
facility [11]. The BeadArray platform is highly miniatur-
ised, using fibre optic bundles as a substrate for a high-
density microarray [12]. It is the combination of this min-
iaturisation with an ability to multiplex up to 1,536 SNP
assays [11] that makes BeadArray an attractive potential
solution to the genotyping bottleneck. A recent study by
Barker and colleagues, with 2,320 SNPs and five samples,
found 99.86% concordance between MSI MDA product
and gDNA [13]. However, since only five samples were
studied it was not possible to evaluate accurately the effi-
cacy of BeadArray on MDA product template, including
estimation of sample exclusion and failure rates. In the
present report we have, therefore, studied 86 MDA prod-
uct samples and 384 SNPs using BeadArray, allowing
comparison with the single-plex methods TaqMan®
(Assays-by-DesignSM, Applied Biosystems, Foster City, CA,
USA) and Invader® (Third Wave Technologies, Inc., Madi-
son, WI, USA) with gDNA.
Results
MDA yield
We selected and sent to MSI 20 ng of 88 gDNA samples for
amplification, from which an average of 200 µg of MDA
product was yielded in 100 µl reactions. The yields ranged
from 85 µg to 280 µg, with 61% of samples yielding
between 100 µg and 200 µg. The HLA-DRB1 genotype of
each MDA sample was entirely concordant with the corre-
sponding gDNA template, verifying the identity of each
MDA sample and ruling out the possibility of
contamination.
When 100 ng of 448 gDNA samples were amplified using
reagents supplied by MSI in kit form and the amplifica-
tion carried out in-house, an average of 155 µg of MDA
product was yielded in 150 µl reactions. The yields ranged
from 31 µg to 260 µg, with 80% of samples yielding
between 100 µg and 200 µg.
Compatibility of MDA product with TaqMan and Invader
Of 88 MDA products and their corresponding gDNAs
tested at 95 SNPs using the TaqMan method of genotyp-
ing there were no samples that consistently failed to pro-
duce any data. This confirmed that, for all samples,
amplification had been sufficiently successful for the Taq-
Man chemistry to perform at most SNPs. Genotype con-
cordance rates between MDA product and gDNA and
genotype failure rates are given in Table 1. These resultsBMC Biotechnology 2004, 4:15 http://www.biomedcentral.com/1472-6750/4/15
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demonstrate that the use of MDA product as a template
for the TaqMan assay produces accurate data comparable
to that from gDNA. We observed that, for the majority of
TaqMan assays, the clustering of data points was less dis-
tinct when MDA product was used as a template, com-
pared to gDNA. Example data from an assay in which
deterioration in clustering was observed are shown in Fig-
ure 1. For a single SNP of the 95 tested, the insulin gene
(INS) -23HphI (rs689), an allelic bias was observed in the
MDA process, which resulted in the merging of the heter-
ozygote cluster with the homozygote cluster of the major
allele, making the correct assignments of genotype impos-
sible, shown in Figure 2 [see additional file 1]. MDA prod-
uct used as a template for the Invader genotyping method
at this SNP produced similarly un-useable data. Using
gDNA template at this SNP, however, both the TaqMan
and Invader methods produced acceptable results, shown
in Figure 2 [see additional file 1], indicating that the allelic
bias was occurring at the MDA stage and not during sub-
sequent genotyping. Interestingly, allelic bias has previ-
ously been observed at two other SNPs at INS in PCR
reactions designed for the Pyrosequencing method (Pyro-
sequencing AB, Uppsala, Sweden) [14]. These results may
indicate that INS may be situated in a sequence region
that is predisposed to such allelic bias and the INS varia-
ble number of tandem repeats polymorphism, only 580
bp 5' to the -23HphI SNP, is a candidate for such an effect.
For 13 additional SNPs for which Invader genotyping was
performed, comparison of genotypes generated from
MDA product with those from gDNA are shown in Table
1.
Two SNPs were genotyped by TaqMan on the 448 samples
amplified using reagents supplied by MSI in kit form (and
the amplification carried out in-house), and on the corre-
sponding gDNAs. The gDNA samples used for amplifica-
tion had been extracted from whole blood. Genotype
concordance rates between MDA product and gDNA and
genotype failure rates are given in Table 1.
Validation of BeadArray genotyping technology with 
gDNA template
We commissioned Illumina to conduct a large-scale
project using BeadArray genotyping technology involving
3,036 samples (2,950 gDNA samples and 86 MDA prod-
ucts) and 384 SNPs i.e. >1.1 million genotypes. In the first
instance, 757 SNP sequences were sent to Illumina for in
silico assay design. These SNPs were selected for their rele-
vance to a range of ongoing projects in our laboratory,
located at genes of strong functional candidacy and within
regions of linkage to type 1 diabetes e.g. the putative
IDDM10 locus on chromosome 10p14-11. All SNPs were
validated, having been identified either from empirically
confirmed SNPs in dbSNP or from our own re-sequencing
efforts. Based on ranking from the in silico design criteria
[15], 404 SNPs from 757 (53%) were suggested as most
suitable for assay development, from which 384 were cho-
sen. Thirty-nine of these failed to be converted into a via-
ble assay (10.2%), leaving a total of 345 working assays.
As well as excluding SNPs that fail to produce robust gen-
otypes, the Illumina protocol excludes samples that do
not consistently perform. Of the total number of samples
10.5% were excluded and as a consequence very few data
points were missing from the data set, resulting in an
apparently low genotype failure rate (Table 2). Within the
2,781 successfully genotyped gDNA sample set, 26 were
duplicate samples. Of these 52 samples at 345 SNPs, the
genotypes of 23 duplicates did not match each other and
19 data points were missing, giving a discordance rate
(error rate) of 0.26% (23 of 8,951 data points).
As our samples were family-based, a quality control check
of misinheritance rates was possible using PedCheck [16].
Of the 345 SNPs, 20 displayed ≥ 10 misinheritances in the
742 families genotyped. For ten of these SNPs, TaqMan
genotyping was attempted in the same samples in order to
verify the results. It was possible to design TaqMan assays
to only seven of the ten SNPs and, of these, only three pro-
duced interpretable data. At these three SNPs the numbers
Table 1: Genotype concordance and failure rates for MDA compared with gDNA across genotyping platforms.
Genotype 
Concordance Rate 
(%)
Genotype Failure Rate (%)
Genotyping 
Platform
Site of MDA 
production
Number of SNPs Number of non-
excluded samples
gDNA and MDA 
product template
gDNA template MDA product 
template
TaqMan MSI 95 88 99.71 2.4 4.0
TaqMan In-house 2 448 99.4 0.7 1.9
BeadArray MSI 345 77 98.8 0.06 0.2
Invader MSI 13 88 99.9 0.9 2.6BMC Biotechnology 2004, 4:15 http://www.biomedcentral.com/1472-6750/4/15
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TaqMan fluorescence data plotted to compare the performance of MDA product with gDNA Figure 1
TaqMan fluorescence data plotted to compare the performance of MDA product with gDNA. This is a typical example of the 
clustering and scoring of TaqMan data for a common SNP in the evaluation of MDA product as a template for TaqMan geno-
typing. (a) End-point data from the 88 gDNA samples used in this evaluation and (b) the corresponding 88 MDA samples. In 
this example there are eight apparent failures for MDA, which are, in fact, empty wells. No genotypes were rejected for gDNA, 
and two genotypes were rejected for the MDA products due to poor clustering.BMC Biotechnology 2004, 4:15 http://www.biomedcentral.com/1472-6750/4/15
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of misinheritances were 41, four and eight, respectively,
by TaqMan, compared to 17, 22 and 14, respectively, by
BeadArray. The number of SNPs with <10 or <5 misinher-
itances from the BeadArray experiment is shown in Table
3, along with our previous year's TaqMan results consid-
ering SNPs with allele frequencies >1%. The poor per-
formance of both Illumina and TaqMan at the ten SNPs
compared in detail, as well as the lab misinheritance rate
for TaqMan (Table 3), indicates that the high misinherit-
ance rates observed for some SNPs in the Illumina exper-
iment is not a technology-specific failing.
Within the panel of 384 SNPs attempted by Illumina, 17
were controls for which we had already produced geno-
typing data by either TaqMan or Invader methods, ena-
bling an evaluation of the BeadArray data for
concordance. Two of these 17 control SNPs failed to be
converted to a working assay, giving 15 SNPs and a maxi-
mum of 2,503 samples that were genotyped in common.
Excluding failed duplicates noted above, comparison of
BeadArray genotypes with existing data revealed a con-
cordance rate of 99.6% (129 discordant in 34,219 com-
parisons), indicating the compatibility of the non-
excluded gDNA samples with BeadArray, and the quality
of existing data. Of the 15 control SNPs, 11 had been gen-
otyped using TaqMan and four using Invader. The con-
cordance rates for each platform were 99.7% using
TaqMan (104 discordant in 25,203 comparisons) and
99.6% using Invader (25 discordant in 9,016 compari-
sons) when compared with BeadArray data, showing no
significant difference between the two platforms.
Compatibility of BeadArray with MDA product
Within the BeadArray experiment described above were
86 MDA products and their corresponding gDNA sam-
ples. These data were directly compared for sample failure
rate and genotype failure rate as shown in Table 2. Bead-
Array genotype concordance rate between MDA product
and gDNA are given in Table 1. These results provide evi-
dence for the compatibility of the non-excluded MDA
products with BeadArray technology. Evaluation of the
Illumina's quality scores revealed no significant difference
between the MDA and gDNA samples for any SNP (t-test
P-value >0.05 for every SNP).
Discussion
In this study we have evaluated the Φ29 polymerase MDA
whole genome amplification method from MSI by assess-
ing the compatibility of its product with the established
TaqMan and Invader genotyping chemistries and with the
highly multiplexed BeadArray genotyping platform. We
have also evaluated Illumina's BeadArray genotyping plat-
form for a large-scale experiment using gDNA.
At 95 SNPs, comparison of TaqMan genotypes generated
from MDA product and gDNA templates revealed a very
good concordance rate but a higher failure rate for MDA
product compared to gDNA. This would need be esti-
mated in a sample size larger than the current n = 88 in
order to be confirmed. This result is comparable to the
smaller study by Tranah et al. [9], in which six SNPs were
genotyped by TaqMan on 172 samples, resulting in 100%
concordance of pre- and post-MDA DNA. In the present
study, the MDA product genotypes were slightly more dif-
ficult to assign, owing to more dispersed clusters. This was
not observed by Lovmar et al. with fluorescent minise-
quencing on Amersham MDA products compared to
gDNA [10]. One marker in our study, which may be unu-
sually prone to allelic bias, was impossible to score using
Table 2: BeadArray sample exclusion and genotype failure rates for MDA product compared with gDNA.
Template Original number of 
samples
Number of 
excluded samples
Exclusion rate Number of 
attempted 
genotypes
Number of failed 
genotypes
Genotype failure 
rate
gDNA 2,950 169 5.7 959,445 590 0.06
MDA product 86 9 10.5 26,565 52 0.2
Table 3: Comparison of misinheritance rates in families genotyped by BeadArray and TaqMan platforms using gDNA.
Genotyping Platform Number of families tested Number of SNPs tested Number of SNPs with <10 
misinheritances
Number of SNPs with <5 
misinheritances
BeadArray 742 300 280 (93.3%) 248 (82.7%)
TaqMan 750 501 479 (95.6%) 409 (81.6%)BMC Biotechnology 2004, 4:15 http://www.biomedcentral.com/1472-6750/4/15
Page 6 of 8
(page number not for citation purposes)
MDA product but was acceptable when using gDNA as a
template (INS -23HphI, rs689).
Compared to the yields indicated in Dean et al. [7], our
average yield from in-house amplification using the rea-
gents in kit form were in the order of five- to six-fold
higher. This was probably due to differences in the two
protocols: for example, our protocol used an increased
reaction volume compared to the protocol used in Dean
et al. [7]. Furthermore, the Dean et al. [7] protocol omitted
the denaturation step, which is now standard practice.
One other potential explanation for this variation is pos-
sible differences between laboratories in the quantitation
of DNA using PicoGreen, the application of which
requires a standard reference data set. We cannot at
present fully resolve the differences in yields between
studies but we can conclude that very large amounts of
DNA are synthesized during the Φ29 reaction and that
this is an excellent template for genotyping. MDA product
should, therefore, be quantified and its concentration on
completion of the MDA reaction not assumed to be con-
sistent. Genotype failure rate, concordance rates with
gDNA and the nature of genotype clustering showed sim-
ilar patterns to service-generated MDA. However, a larger
number of SNP markers would need to be genotyped on
the MDA product using purchased kit reagents in order to
verify these figures for in-house amplifications.
In the evaluation of MDA product in conjunction with
BeadArray technology, the high concordance rate between
genotypes obtained from MDA product and gDNA tem-
plates is encouraging. A concordance rate of 99.86% has
been reported by Barker et al. using 2,320 SNPs and five
samples [13]. However, as our study used 86 samples, we
were able to observe differences in genotype failure rate
between the different templates, not noted in the previous
study [11]. As with the TaqMan evaluation, BeadArray had
a higher genotype failure rate for MDA product compared
to gDNA (0.2% for MDA versus 0.06% for gDNA). We did
not find any evidence for allele drop-out with MDA com-
pared to gDNA. BeadArray genotyping excluded more
MDA samples than gDNA samples (10.5% for MDA ver-
sus 5.7% for gDNA) indicating that gDNA is a superior
genotyping template for BeadArray technology. This 2-
fold exclusion rate for MDA is consistent with the approx-
imately 2 to 3-fold genotype failure rate of MDA typically
observed with TaqMan and Invader, compared to gDNA
(unpublished data).
The performance of MDA product is continuously being
monitored in our laboratory. In a study blinded to all gen-
otypers and database administrators, 288 family-based
gDNA samples (prepared by the salting out method),
were replaced with MDA product and left in continual use
in our genotyping pipeline for 12 months. The change
went undetected by all users. The failure rate for MDA was
3.34% for 15,921 genotypes, compared to 2.39% for
19,272 gDNA genotypes. Therefore, this improvement in
the MDA performance for TaqMan is likely to be applica-
ble to BeadArray, which improves the feasibility of map-
ping susceptibility loci in complex traits.
When using a highly multiplexed, highly automated gen-
otyping platform, slight reductions in the quality of tem-
plate material are likely to have a greater adverse effect on
data than in scenarios in which markers are assessed indi-
vidually and manual scoring is undertaken. Our results
indicate that MDA is an adequate solution for the vast
majority of SNP markers, even in this highly multiplexed
allelic assay platform.
It is noted that 5.8% of markers that passed the Illumina
acceptable scoring threshold were in fact showing high
misinheritance rates in our family samples. This problem
was at the same magnitude as TaqMan for individually
genotyped markers. This highlights the importance of
checking potential positive results with a second genotyp-
ing technology.
MDA should allow the continuation of genetic analysis on
archived DNA in researchers' freezers worldwide, provid-
ing the very necessary increases in sample sizes so urgently
required [1,2,17].
Conclusions
The combination of BeadArray high throughput, multi-
plex genotyping and amplified DNA (MDA product) suc-
cessfully produced high quality genotype data thereby
improving the feasibility and efficiency of mapping com-
mon disease susceptibility genes despite limited stocks of
gDNA samples.
Methods
MDA product preparation
For both the validation experiments (MDA product as a
template for TaqMan and Invader genotyping) and for the
combined experiment (MDA product as a template for
BeadArray genotyping) the same MDA samples were
tested. We sent to MSI 20 ng (5 µl at 4 ng/µl) of 88 gDNA
samples for amplification, which was performed as a serv-
ice according to the protocol for human gDNA with the
omission of the denaturing step [7]. These gDNA samples
had been extracted from cell pellets of EBV derived cell
lines using a standard chloroform protocol that produces
very high quality and stable gDNA [18]. The MDA product
returned to us was quantified using PicoGreen dsDNA
quantitation reagent (Molecular Probes Europe B.V., Lei-
den, the Netherlands).BMC Biotechnology 2004, 4:15 http://www.biomedcentral.com/1472-6750/4/15
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In order to verify the identity of each MDA-produced sam-
ple, genotyping was performed at HLA-DRB1 and com-
parison made with data generated from the corresponding
gDNA. HLA-DRB1 genotyping was performed using the
Dynal Auto RELI™ SSO HLA-DRB Test system (Dynal® Bio-
tech, Wirrel, UK) for each gDNA sample and their MDA
products. Although, these samples were amplified by MSI
as a service, the reagents are also available from MSI in a
kit form for amplification in-house. Following the ampli-
fication by MSI we have amplified 448 DNA samples by
using the reagents in kit form and 100 ng (25 µl at 4 ng/
µl) gDNA template in 100 µl reactions. In the interim, one
major change to the MDA protocol had taken place, the
inclusion of a denaturation of the DNA template prior to
amplification. Previously no denaturation step took place.
Two TaqMan markers were tested on these 448 samples
and the genotype failure rate calculated.
Evaluation of MDA product as a template for TaqMan and 
Invader genotyping
SNP TaqMan assays were carried out for allelic discrimina-
tion, 8 ng of DNA (2 µl at 4 ng/µl) used in a 5 µl total reac-
tion volume. TaqMan genotypes from the 88 MDA
samples, described above, were compared with TaqMan
genotypes generated from their corresponding gDNAs, at
95 SNPs, with a broad range of allele frequencies. The
Invader method was used to genotype 13 additional SNPs
on the same samples. Comparison was made between
data generated from both templates by the measurement
of genotype failure and genotype concordance rates.
Evaluation of BeadArray genotyping technology and its 
compatibility with MDA product
Of the 384 SNPs selected for genotyping 3,036 samples,
17 were control SNPs for which we had existing genotype
data, generated by either TaqMan or Invader methods,
with which comparison of genotype failure and genotype
concordance rates were made. These 384 SNPs covered a
broad range of allele frequencies.
Incorporated into this experiment was an assessment of
suitability and compatibility of the BeadArray genotyping
method with MDA product. This involved 86 of the 88
amplified samples, described above, for which genotyp-
ing was attempted at all 384 SNPS. Concordance between
genotypes generated from MDA product and gDNA tem-
plates, together with the genotype and sample failure rates
of each template type were measured.
In our laboratory we store genotyping data in a MySQL
database on a Sun server. The volume of data expected
from Illumina was the equivalent of 6 months' in-house
genotyping. We separated phenotypic and pedigree infor-
mation, which is associated with a sample, from genotype
data, which is associated with a DNA plate and well posi-
tion, with a link table to relate the two. Sample aliases are
also supported, so that no recoding of identifiers is
required, either to export or import Illumina data [19].
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